Table 1 Characteristics of studies included in the meta-analysis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Trial** | **SGLT2 inhibitor** | **EF at baseline** | **Median follow-up** | **Diabetes Mellitus (DM) status of participants** | **Renal function at baseline** | **Mean Baseline Body Mass Index (kg/m2)** |
| **EMPEROR – PRESERVED** | Empagliflozin | EF > 40% | 26.2 months | DM + non-DM | eGFR >20 ml/min/1.73m2*(mean 60.6 ml/min/1.73m2)* | 29.8 |
| **VERTIS-CV\*** | Ertugliflozin | EF > 45% | 3.0 years | DM | eGFR <60 & ≥60 ml/min/1.73m2 | 32.6 |
| **DECLARE- TIMI 58** | Dapagliflozin | EF > 45% | 4.2 years | DM | eGFR > 60 ml/min/1.73m2 | 31.6 |
| **SOLOIST- WHF** | Sotagliflozin | EF ≥ 50% | 9.2 months | DM | eGFR >30 ml/min/1.73m2*(median 50.5 ml/min/1.73m2)* | 31.1 |
| **SCORED** | Sotagliflozin | EF ≥ 50% | 16 months | DM | eGFR 25 – 60 ml/min/1.73m2 | 31.9 |

 \*For the purposes of this meta-analysis, only the subgroup of patients with EF >45% was included